08.16.07
Pharmatek Laboratories, Inc. has added cytotoxic and high-potent drug development capabilities to its pharmaceutical chemistry development services. These services include: analytical method development, preformulation testing, formulation development, manufacturing for early phase clinical trials, release testing, and stability testing and storage.
"This expansion was driven by an increase in demand for cytotoxic and high-potent drug development and manufacturing outsourcing among our clients," said Dr. Jeffrey Bibbs, chief executive officer of Pharmatek. "This added capability enables us to provide a broader level of services to our clients with cytotoxic and high-potent candidates."
The company's cytotoxic and high-potent development services will take place in a separate dedicated facility. Manufacturing capability includes two validated and licensed class 100,000 high-containment suites designed with barrier technology for cGMP manufacturing of final form drug products, with dedicated HVAC and HEPA filtration systems to ensure product containment within the suites.
"This expansion was driven by an increase in demand for cytotoxic and high-potent drug development and manufacturing outsourcing among our clients," said Dr. Jeffrey Bibbs, chief executive officer of Pharmatek. "This added capability enables us to provide a broader level of services to our clients with cytotoxic and high-potent candidates."
The company's cytotoxic and high-potent development services will take place in a separate dedicated facility. Manufacturing capability includes two validated and licensed class 100,000 high-containment suites designed with barrier technology for cGMP manufacturing of final form drug products, with dedicated HVAC and HEPA filtration systems to ensure product containment within the suites.